India institutes price caps for orthopedic knee implants

Indian regulators are capping prices of orthopedic knee implants as the country looks to lower the cost of medical devices. The country’s drug pricing authority said today that orthopedic implants in the country had unjustified, unreasonable and irrationally high trade margins, which led to exorbitant pricing. Minister of Chemicals and Fertilizers Ananth Kumar said the prices had been capped “in public interest” during a new briefing today. With the change, Kumar said that commonly used cobalt chromium knee implants, previously priced up to $3,895 (INR ₹250,000), would be capped at $852 (INR ₹54,720). Kumar went on to say that the country would not allow “illegal profiteering, unethical profiteering.” The move is the most recent step from the Indian government to reduce the cost of drugs and medical devices in the country. In February, India capped the price of coronary stents, cutting prices by as much as 75%, resulting in backlash from major medical device manufacturers including Medtronic (NYSE:MDT) and Abbott (NYSE:ABT). Both Abbott and Medtronic claimed the caps would cause innovation to stagnate in the country and limit its access to new technologies and threatened to exit the country’s market with their devices. The Indian NPPA rejected applications from both companies to withdraw stents from the country and asked both to continue supplying the devices. Abbott, Medtronic and Boston Scientific (NYSE:BSX) said they were still ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Healthcare Reform Orthopedics Regulatory/Compliance Abbott India Medtronic Source Type: news